Document is current
Any future updates will be listed below
-
Authors
Vij, Ridhima https://orcid.org/0000-0003-3130-5133
Kim, Hosu
Park, Hyeonggeun
Cheng, Thanh
Lotfi, Djamchid
Chang, Donna
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04798066 at ClinicalTrials.govDocuments that mention this clinical trial
Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program
https://doi.org/10.1186/s13287-023-03522-1
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 26 September 2023
First Online: 5 October 2023
Declarations
:
: Title of the approved project: Intermediate-Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with post-COVID-19 Syndrome. Approval committee: The study was approved by the Western Institutional Review Board located in Olympia, Washington, and conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Approval number: 20210333, Date of approval: March 09, 2021. All participants provided written informed consent. Clinical trial registration: .
: A written consent form for publication of the clinical details was obtained from all subjects.
: Ridhima Vij is an employee of Hope Biosciences Research Foundation and declares no competing interests that could have appeared to influence the work reported in this paper. Hosu Kim, Hyeonggeun Park and Donna Chang declare the following financial interests which may be considered as potential competing interests: The above listed authors are employees of Hope Biosciences LLC.
